68Ga-grazytracer for Advanced Hepatobiliary Cancer
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
Recruiting
Observational Study
Hepatobiliary Malignancy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 75
Sex
Any
Study type
Observational
Participants needed
40 (estimated)
Sponsor
Ruijin Hospital · Other
Who this trial is looking for
This trial is looking for adults with advanced hepatobiliary cancer who might benefit from immunotherapy. Participants will undergo tests to see how well a substance called 68Ga-grazytracer can predict their response to treatment.
Are You a Good Fit for This Trial?
You may be able to join if
I have been diagnosed with advanced hepatobiliary cancer.
I am 18 to 75 years old.
I am in good health with an expected survival of more than 6 months.
I can sign and date the informed consent form.
I will follow the research procedures.
You may not be able to join if
I have a serious illness that makes me unsuitable for this study.
I have intestinal perforation or complete intestinal obstruction.
I have uncontrolled diabetes or high blood sugar on the day of the trial.
I am pregnant, may be pregnant, or breastfeeding.
I do not comply with medical advice.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced hepatobiliary malignancies.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
1. Pathological and clinical diagnosis of advanced hepatobiliary malignancy requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines
2. Signed and dated informed consent form
3. Commitment to comply with research procedures and co-op…
Inclusion Criteria:
1. Pathological and clinical diagnosis of advanced hepatobiliary malignancy requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines
2. Signed and dated informed consent form
3. Commitment to comply with research procedures and co-operation in the implementation of the full research process
4. aged 18-75 years old
5. The patient is in good general condition with an expected survival of \> 6 months
Exclusion Criteria:
1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
2. Intestinal perforation, complete intestinal obstruction
3. Uncontrolled diabetes patients or fasting blood glucose levels ≥11 mmol/L on the day of the trial
4. Pregnant women and women who may be pregnant, women who are breastfeeding.
5. Non-compliant person
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
